Julia Berretta

Julia Berretta is Chief Executive Officer of Genespire. She also holds an appointment as an independent Board member of Treefrog therapeutics, an innovative stem cell company. Julia was formerly part of the Executive Committee of Cellectis S.A. a Nasdaq listed company developing allogeneic CAR-T cells in oncology, where she held various positions including VP of Business Development & Strategic Planning. While at Cellectis, she has been leading the business development department and has been instrumental in setting up transformational strategic partnerships with pharmaceutical companies.

She also held a position as an independent Board member of Epsilen Bio srl, a biotechnology company developing novel therapies based on epigenetic silencing. Julia is french and italian and is a scientist by training. She holds a PhD in Molecular Biology, from Université Paris XI, as well as a Masters in Management from Neoma Business School.